Form 4: Enliven Therapeutics CFO Benjamin Hohl Exercises Options and Sells Shares

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares on April 28, 2025, according to a Form 4 filing with the SEC.

Summary

• On April 28, 2025, Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, exercised options to purchase 3,250 shares of common stock at a price of $2.48 per share.
• Hohl then sold 3,181 shares at a weighted average price of $18.6792 and 69 shares at a weighted average price of $19.1162.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Hohl directly owns 23,000 shares of common stock and holds options for 125,306 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine transactions by an officer under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Insider transactions are common across publicly traded companies, and the legality of these transactions hinges on compliance with SEC regulations, particularly Rule 10b5-1, which allows insiders to establish pre-arranged trading plans to avoid accusations of trading on non-public information.
• Companies like Pfizer, Amgen, and Johnson & Johnson also have executives who regularly file Form 4s, reflecting the normal course of stock option exercises and sales.
• The size and frequency of these transactions can vary widely based on individual financial planning and company compensation structures.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they involve the sale of shares by a company insider, potentially creating slight downward pressure on the stock price in the short term.

Key Dates

Keywords

Form 4, Enliven Therapeutics, ELVN, Benjamin Hohl, CFO, stock options, share sale, Rule 10b5-1, insider trading